An Unusual Case of Two Paraneoplastic Neurological Syndromes in a Patient With Lung Cancer

Paraneoplastic immune-mediated disorders have been well described in the literature. However, it is still relatively rare. The incidence has increased over the past decade due largely to the discovery of more autoantibodies. With a better understanding of the pathophysiology of different autoantibodies and clinical phenotypes, we are often able to diagnose clinically some specific paraneoplastic autoimmune neurological syndromes. We may also predict the response to treatment based on the autoantibody class. We are presenting a very unusual case of two completely different paraneoplastic syndromes with two different autoantibodies, gamma-aminobutyric acid-B (GABAB) and collapsin response mediator protein 5 (CRMP5), in a patient with underlying small-cell lung cancer. We will discuss the differences in the two antibody syndromes, their significance, and their management.

[1]  C. Vedeler,et al.  CRMP5 Antibodies—Diagnostic Challenges , 2021, Frontiers in Neurology.

[2]  Zhimei Li,et al.  Clinical Characteristics of Anti-GABA-B Receptor Encephalitis , 2020, Frontiers in Neurology.

[3]  J. Al-Hashel,et al.  Paraneoplastic Limbic Encephalitis Associated with Anti-CV2/CRMP5 Antibodies Secondary to Thymoma in an Adolescent , 2020, Case Reports in Neurology.

[4]  G. Gigli,et al.  Epidemiology of paraneoplastic neurological syndromes: a population-based study , 2019, Journal of Neurology.

[5]  F. Lui Autoimmune Encephalitis a Mini Review , 2019, Advancements in Case Studies.

[6]  J. Dalmau,et al.  Antibody-Mediated Encephalitis. , 2018, The New England journal of medicine.

[7]  C. Klein,et al.  Autoimmune CRMP5 neuropathy phenotype and outcome defined from 105 cases , 2018, Neurology.

[8]  B. Boeve,et al.  Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis , 2018, Annals of neurology.

[9]  K. Chu,et al.  Treatment strategies for autoimmune encephalitis , 2017, Therapeutic advances in neurological disorders.

[10]  C. Geis,et al.  Autoantibodies to Synaptic Receptors and Neuronal Cell Surface Proteins in Autoimmune Diseases of the Central Nervous System. , 2017, Physiological reviews.

[11]  R. Liblau,et al.  CD4+ and CD8+ T cells are both needed to induce paraneoplastic neurological disease in a mouse model , 2017, Oncoimmunology.

[12]  S. I. Lee,et al.  The Laboratory Diagnosis of Autoimmune Encephalitis , 2016, Journal of epilepsy research.

[13]  J. Dalmau,et al.  Autoimmune encephalopathies , 2015, Annals of the New York Academy of Sciences.

[14]  J. Dalmau,et al.  GABAB receptor antibodies in limbic encephalitis and anti-GAD–associated neurologic disorders , 2011, Neurology.

[15]  Josemir W Sander,et al.  Seizures and epilepsy in oncological practice: causes, course, mechanisms and treatment , 2006, Journal of Neurology, Neurosurgery & Psychiatry.

[16]  O. O'toole,et al.  Encephalitis associated with autoantibodies binding to g-aminobutyric acid-A, g-aminobutyric acid-B and glycine receptors: immunopathogenic mechanisms and clinical characteristics , 2015 .